US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Biohit Oyj - Managers' Transactions Panu Hendolin

Person subject to the notification requirement Name: Panu  Hendolin Position: Other senior manager Issuer: Biohit Oyj LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 37028/6/6 ____________________________________________ Transaction date: 2023-08-23 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009005482 Nature of transaction: ACQUISITION Transaction details (1): Volume: 400 Unit price: 2 EUR Aggregated transactions (1): Volume: 400 Volume weighted average price: 2 EUR _________________

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2023

Biohit Oyj Half Year Financial Report 9 August 2023 at 9:30 am local time (EET) SUMMARY January-June 2023 · Revenue EUR 6.5 million (EUR 6.1 million) · Revenue increased by 6.2% compared to H1/2022 · Operative EBITDA EUR 1.8 million (EUR 1.7 million) · EBIT EUR 1.5 million (EUR 1.3 million) · Cash at the end of the period EUR 1.7 million (EUR 2.1 million 31 December 2022) · Fair value of Genetic Analysis AS investment EUR 0.2 million (EUR 0.3 million 31 December 2022) · Revenue from international operations 98.4% (98.2%) of total revenue · Equity ratio 73.2% (

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 15, 2023 at 2:00 pm local time (EEST) Biohit Oyj’s Board of Directors has in its meeting on June 14 elected Ph.D (Jur.), LL.M. Vesa Silaskivi as the Chairman of the Board of Directors. Silaskivi is an experienced board professional and thus a valuable contributor to the company’s growth. Additional information: CEO Jussi Hahtela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fiwww.biohithealthcare.com   Biohit in brief Biohit Oyj is a globally operating Finnish

Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of the Annual General Meeting, June 14, 2023 at 6.00 pm local time (EET) The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday June 14, 2023 approved the financial statements for the financial year 2022. AGM decided to discharge the members of the Board of Directors and the President and CEO from liability for the financial year 2022. AGM decided to approve the Remuneration Report of the company’s Governing Bodies presented to the AGM; the decision is advisory. Distribution of dividends The AGM resolved in accordance with the proposal of the Board of

Notice of Biohit Oyj’s Annual General Meeting

Biohit Oyj Stock Exchange Release May 24, 2023 at 12:00 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, June 14, 2023 starting at 2:00 pm at the Helsinki Stock Exchange Building, for which the address is Fabianinkatu 14, 00100 Helsinki. The reception of registered participants and the distribution of voting papers at the meeting venue will start at 1:00 pm. A. Matters on the agenda of the Annual General Meeting 1.      Opening of the meeting 2.      Calling the meeting to order 3.      Election

Biohit Oyj B-shares Subscribed with Stock Options I 2021A and I 2022A

Biohit Oyj Stock Exchange Release March 30, 2023 at 11:00 a.m. (EEST) A total number of 68,000 new Biohit Plc B-shares have been subscribed for with stock options I 2021A and stock options I 2022A between 1 March 2023 and 17 Mach 2023. These shares have been entered into the Trade Register on March 30, 2023, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on Nasdaq Helsinki Ltd as of Mach 31, 2023 together with the existing B-shares. The share subscription price was EUR 1.00 per share respectively. The

Biohit Plc - Managers' transactions - Hahtela

Person subject to the notification requirement Name: Hahtela, Jussi Position: Chief Executive Officer Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102846_10 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 20000 Unit price: 1.00 EUR Aggregated transactions (1):

Biohit Plc - Managers' transactions - Patrakka

Person subject to the notification requirement Name: Patrakka, Ilari Position: Other senior manager Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102303_5 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 8000 Unit price: 1.00 EUR Aggregated transactions (1):

Biohit Plc - Managers' transactions - Hendolin

Person subject to the notification requirement Name: Hendolin, Panu Position: Other senior manager Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102635_8 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 8000 Unit price: 1.00 EUR Aggregated transactions (1):

Biohit Plc - Managers' transactions - Söderström

Person subject to the notification requirement Name: Söderström, Daniela Position: Other senior manager Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102700_9 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 8000 Unit price: 1.00 EUR Aggregated transactions (1):

Biohit Plc - Managers' transactions - Sorvo

Person subject to the notification requirement Name: Sorvo, Jussi Position: Chief Financial Officer Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102454_6 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 8000 Unit price: 1.00 EUR Aggregated transactions (1):

Biohit Plc - Managers' transactions - Elomaa

Person subject to the notification requirement Name: Elomaa, Suvi Position: Other senior manager Issuer: Biohit Plc LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20230321102534_7 ____________________________________________ Transaction date: 2023-03-20 Venue not applicable Instrument type: SHARE ISIN: FI0009005482 Nature of the transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 8000 Unit price: 1.00 EUR Aggregated transactions (1): Volume:

Publication of Biohit Oyj Renumeration Report 2022

Biohit Oyj Renumeration Report March 22, 2023 at 9:30 am local time (EET) Biohit Oyj’s Remuneration Report for the Governing Bodies is published today in PDF format. The Remuneration Report for the Governing Bodies is attached to this stock exchange release and also available at https://www.biohithealthcare.com/en/investors/. Additional information: CEO Jussi Hahtela, Biohit Oyjtel. +358 9 773 861investor.relations@biohit.fiwww.biohithealthcare.com  Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company.

Publication of Biohit Oyj Annual Report 2022

Biohit Oyj Annual Financial Report March 22, 2023 at 09:30 am local time (EET) Biohit Oyj’s Annual Report 2022 is published today in PDF and XHTML format. The annual report contains financial statements for 2022, the Report of the Board of Directors and Corporate Governance Statements. Information in ESEF format has not been audited. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website: Annual Reports - Biohit Healthcare  CEO Jussi Hahtela, Biohit Oyj tel.

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2022

Biohit Oyj Financial Statement Release 15 February 2023 at 9:30 am local time (EET) SUMMARY January-December 2022       · Revenue EUR 11.0 million (EUR 9.4 million) · Revenue grew by 17.0% compared to 2021 · Operative EBITDA EUR +1.8 million (EUR 0,5 million) · Cash at the end of the period EUR 2.1 million (EUR 1.1 million) · Fair value of Genetic Analysis AS investment EUR 0.3 million (EUR 0.9 million 31 December 2021) · Revenue from international operations 97.9% (97.5%) of total revenue · Equity ratio 68.3% (76.3%) July-December 2022 · Revenue EUR 4.8

Changes to Biohit Oyj’s management: Change of R&D Director

Publishing on December 15, 2022 at 2:00 pm local time (EEST) Biohit Oyj’s R&D Director PhD and Associate Professor Minna Mäki has resigned. Current Head of Technical Product Management Panu Hendolin has been appointed to new R&D Director. Hendolin has worked at Biohit as R&D and Production Director in 2007-2008, as well as 2012-2017, and he returned to the company in February 2022. In the meanwhile, Hendolin worked as Production Director at United Medix Laboratories Oy and Chief Technology Officer at Sulapac Oy. Hendolin has the degree of Ph.D. in molecular medicine. CEO Jussi

Biohit Oyj - Managers' Transactions - Hendolin

Person subject to the notification requirementName: Panu HendolinPosition: Other senior manager Issuer: Biohit OyjLEI: 74370089ATTSNBXJVT29Notification type: INITIAL NOTIFICATIONReference number: 21872/4/12____________________________________________ Transaction date: 2022-11-30Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name: I 2021 ANature of the transaction: ACCEPTANCE OF A STOCK OPTION(X) Linked to stock option programme Transaction details(1): Volume: 8000 Unit price: 0 EURAggregated

Biohit Oyj - Managers' Transactions - Sorvo

Person subject to the notification requirementName: Jussi SorvoPosition: Chief Financial Officer Issuer: Biohit OyjLEI: 74370089ATTSNBXJVT29Notification type: INITIAL NOTIFICATIONReference number: 21886/4/6____________________________________________ Transaction date: 2022-11-30Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name: I 2021ANature of the transaction: ACCEPTANCE OF A STOCK OPTION(X) Linked to stock option programme Transaction details(1): Volume: 8000 Unit price: 0 EURAggregated

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2023

Publishing on November 30, 2022 at 2:00 pm local time (EEST)   Biohit Oyj will release its financial statements for 2022 on Wednesday February 15th, 2023, at 9:30 am. The Annual report, which contains the Financial Statement for 2022 and the Report of the Board of Directors, will be published on Wednesday March 22nd, 2023, at 9:30 am. Biohit Oyj’s Annual General Meeting has been planned for Wednesday 14th of June 2023 at 2:00 pm. The Board of Directors will call the General meeting at a later date. Half year financial report for period January-June (H1) 2023 will be published

Biohit Oyj Board of Directors decided on new option scheme

Biohit Oyj Stock Exchange Release November 29, 2022 14:00 EET Biohit Oyj’s Board of Directors has, based on authorization of Biohit Oyj’s General Shareholders’ Meeting on June 15, 2022, decided on new option scheme to Group’s key personnel. Option rights are part of the Biohit Oyj’s and its group of companies’ motivation and reward system and therefore there is a weighty financial reason for the scheme. The maximum total number of the option rights to be granted is 160.000. The option rights entitle to subscribe a maximum total amount of 160.000 class B- shares of Biohit Oyj. Option

Strong scientific Support for Biohit’s GastroPanel in International Consensus Report

The latest international Maastricht/Florence Consensus Report on management of Helicobacter pylori infections recommends several indications of use for Biohit’s GastroPanel biomarkers. This report has been prepared by a  wide panel of international experts. It gives very strong evidence of the benefits of GastroPanel test in diagnosing H. pylori infection, finding causes for dyspepsia and reflux symptoms, as well as evaluating risks for gastric and esophageal cancer, and early perception of them. GastroPanel detects both H. pylori infection and atrophic gastritis (damage of stomach

Biohit GastroPanel enters into global market by co-operation with Randox

GastroPanel- availability expands substantially when Randox started the global sales of its CE-labelled  MULTIPLEX GASROINTESTINAL PANEL-test based on the Biohit license (1). Randox is a British health technology enterprise operating on global market, with the annual turnover of around 730 million euro in 2021. GastroPanel is a diagnostic blood test developed by Biohit Oyj, detecting Helicobacter infection in the stomach, atrophic gastritis (stomach mucosal a trophy) as well as the level of gastric acid output, thus disclosing the potential risks associated with these conditions, e.g.

Changes to Biohit Oyj’s management

Publishing on September 6, 2022 at 14:00 am local time (EEST) MSc (Econ and Bus Admin) Jussi Sorvo (b. 1990) has been appointed Chief Financial Officer and as a member of the Management Team of Biohit Oyj starting September 7th, 2022. He will also be responsible for HR and ICT functions. Sorvo will report to CEO Jussi Hahtela. Sorvo has worked at Biohit as a business controller since June 2021. Previously he has worked at PwC as an auditor and in data-analytics utilization and other reporting development projects. Additional information: investor.relations@biohit.fiwww.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe